StockData
ELI LILLY & Co logo

ELI LILLY & Co

LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3025% above fair value
$1410.99−6.55 (-0.46%)

Close on Nov 2, 2026Market cap $1.33TP/E 45.8Yield 0.44%

Eli Lilly Zyprexa (olanzapine) by Quarter

Zyprexa (olanzapine) — Worldwide revenue YoY (%) [legacy] (%)

QuarterlyAnnual

Eli Lilly Zyprexa (olanzapine): -98.0% in Q3 2024, down 171.4 pts from a year earlier. That is the lowest of the 17 quarters on record here. No newer figure appears in the documents we track.

Latest, Q3 2024
-98.0%
Period ended Sep 30, 2024
Change on a year earlier
-171.4 pts
73.4% in Q3 2023
History
17 quarters
Since Q1 2018
Sources
17
Documents cited below

Where the Q3 2024 figure comes from

“|| Zyprexa (4) | 1.9 | 29.8 | 31.7 | 1,481.4 | (98)”

Source: Form 10-Q FY2024Q3 (filed 2024-10-30) ↗

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedZyprexa (olanzapine) — Worldwide revenue YoY (%) [legacy] (%)Year on yearSource
Q3 2024Sep 30, 2024-98.0%-171.4 ptsForm 10-Q FY2024Q3 (filed 2024-10-30) ↗
Q3 2023Sep 30, 202373.4%+93.4 ptsForm 10-Q FY2023Q3 (filed 2023-11-02) ↗
Q3 2022Sep 30, 2022-20.0%-10.0 ptsForm 10-Q FY2022Q3 (filed 2022-11-01) ↗
Q2 2022Jun 30, 2022-8.0%-7.0 ptsForm 10-Q FY2022Q2 (filed 2022-08-04) ↗
Q1 2022Mar 31, 2022-3.0%0.0 ptsForm 10-Q FY2022Q1 (filed 2022-04-29) ↗
Q3 2021Sep 30, 2021-10.0%-17.0 ptsForm 10-Q FY2021Q3 (filed 2021-10-27) ↗
Q2 2021Jun 30, 2021-1.0%+6.0 ptsForm 10-Q FY2021Q2 (filed 2021-08-03) ↗
Q1 2021Mar 31, 2021-3.0%+5.0 ptsForm 10-Q FY2021Q1 (filed 2021-04-30) ↗
Q3 2020Sep 30, 20207.0%+11.0 ptsForm 10-Q FY2020Q3 (filed 2020-10-28) ↗
Q2 2020Jun 30, 2020-7.0%+11.0 ptsForm 10-Q FY2020Q2 (filed 2020-07-31) ↗
Q1 2020Mar 31, 2020-8.0%+5.0 ptsForm 10-Q FY2020Q1 (filed 2020-05-01) ↗
Q3 2019Sep 30, 2019-4.0%+18.0 ptsForm 10-Q FY2019Q3 (filed 2019-10-25) ↗
Q2 2019Jun 30, 2019-18.0%-9.0 ptsForm 10-Q FY2019Q2 (filed 2019-08-02) ↗
Q1 2019Mar 31, 2019-13.0%+4.0 ptsForm 10-Q FY2019Q1 (filed 2019-05-02) ↗
Q3 2018Sep 30, 2018-22.0%–Form 10-Q FY2018Q3 (filed 2018-11-06) ↗
Q2 2018Jun 30, 2018-9.0%–Form 10-Q FY2018Q2 (filed 2018-07-25) ↗

Cite this data

StockData. (2026). Eli Lilly Zyprexa (olanzapine) (%), quarterly Q1 2018–Q3 2024 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med-zyprexa-yoy

See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.